Soroka University Medical Center, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Anaesthesia. 2014 Nov;69(11):1251-7. doi: 10.1111/anae.12736. Epub 2014 May 22.
Sugammadex is a drug used to reverse neuromuscular blockade induced by rocuronium or vecuronium. It has not yet been approved by the Food and Drug Administration in the USA due to concerns regarding hypersensitivity. The objective of this review was to identify similarities in the presentation of hypersensitivity reactions to sugammadex. A comprehensive search was performed in PubMed, Scopus and Web of Science for cases reporting hypersensitivity reactions to sugammadex. In addition, we contacted regulatory agencies and the company marketing the drug for unpublished reports. Reports were included if they were in English, primary investigations, lacked an alternative probable explanation for the reaction and included a comprehensive description of the hypersensitivity. We identified 15 cases of hypersensitivity following sugammadex administration. All cases that reported exact timing (14/15) occurred in 4 min or less. Most of the patients (11/15; 73%) met World Anaphylaxis Organization criteria for anaphylaxis. Awareness must be raised for the possibility of drug-induced hypersensitivity during the critical 5-min period immediately following sugammadex administration.
苏伽 （ Sugammadex ） 是一种用于逆转罗库溴铵或维库溴铵引起的神经肌肉阻滞的药物。由于对过敏反应的担忧，它尚未获得美国食品和药物管理局的批准。本综述的目的是确定对苏伽麻丹过敏反应的表现相似之处。在 PubMed 、 Scopus 和 Web of Science 中进行了全面检索，以查找报告苏伽麻丹过敏反应的病例。此外，我们还联系了监管机构和药物营销公司，以获取未发表的报告。如果报告为英文、为初步调查、对反应缺乏替代的可能解释且包括过敏反应的全面描述，则将其纳入。我们确定了 15 例使用苏伽麻丹后发生的过敏反应。所有报告确切时间（14/15）的病例均在 4 分钟或更短时间内发生。大多数患者（11/15；73%）符合世界过敏组织的过敏反应标准。在使用苏伽麻丹后 5 分钟的关键时间内，必须提高对药物引起的过敏反应的可能性的认识。
